Is Harrow Health, Inc. (HROW) a Buy, Sell, or Hold?
NASDAQ : HROW
Harrow Health, Inc. — Institutional Ownership
$38.45 USD
-$3.43 (-8.19%)
- Volume
- 888.58K
- Average Volume
- 830.26K
- Market Capitalization
- $1.43B
- P/E Ratio
- -97.96
- Dividend Yield
- 0.00%
- Price Target
- $70.00
- Year High
- $54.85
- Year Low
- $28.54
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.48
Institutional Ownership Summary
Institutional Ownership %
1.40%
Investors Holding
36
change: -190 | last: 226
Increased Positions
9
change: -101 | last: 110
Reduced Positions
9
change: -69 | last: 78
New Positions
2
change: -42 | last: 44
Sold Positions
185
change: 145 | last: 40
Total Calls
-
Total Puts
-
Put-Call Ratio
0.00
change: -50.5506 | last: 0.5055
Total Invested
21.67M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-11 | Opaleye Management Inc. | 2.83M | 7.61% |
| 2026-03-27 | The Vanguard Group | - | 0.00% |
| 2026-03-11 | Daniel Kaufman | 1.88M | 5.04% |
| 2025-04-07 | Mark L. Baum | 4.06M | 10.69% |
| 2024-02-13 | The Vanguard Group - 23-1945930 | 1.81M | 5.15% |
| 2024-01-29 | (1) BlackRock, Inc. | 2.22M | 6.30% |
| 2024-01-09 | Private Capital Management, LLC (46-3167283) | 3.63M | 10.34% |
| 2022-02-14 | Ophir Global Opportunities Fund | 1.91M | 7.08% |
| 2022-02-10 | 13-3127734 | 1.2M | 4.46% |
| 2022-02-10 | 26-0385758 | 1.2M | 4.46% |
| 2021-07-12 | (1) BlackRock, Inc. | 413.86K | 1.60% |
| 2021-04-27 | Mark L. Baum | 2.37M | 8.60% |
| 2021-02-10 | 26-0385758 | 1.49M | 5.80% |
| 2021-02-10 | 13-3127734 | 1.49M | 5.80% |
| 2021-02-02 | (1) BlackRock, Inc. | 1.53M | 6.00% |
| 2018-11-23 | Imprimis Pharmaceuticals, Inc. | 3.5M | 20.70% |
| 2018-09-07 | Opaleye, L.P. | 9.0 | 5.11% |
| 2018-09-07 | Opaleye Management Inc. | 9.0 | 5.11% |
| 2017-04-19 | Brett Conrad | 1.42M | 7.10% |
| 2017-03-29 | Brett Conrad | 1.31M | 6.58% |
| 2017-02-23 | Opaleye Management Inc. | 720K | 3.87% |
| 2017-02-23 | James Silverman | 720K | 3.87% |
| 2017-02-14 | Marathon Asset Management, L.P. | 833.33K | 4.50% |
| 2016-03-21 | Marathon Asset Management, L.P. | 833.33K | 6.40% |
| 2016-02-16 | Manchester Management Company, LLC | - | 0.00% |
| 2016-02-16 | James E. Besser | - | 0.00% |
| 2015-05-20 | Donald Miloni | 747.06K | 7.82% |
| 2015-01-22 | James E. Besser | 608.36K | 6.60% |
| 2015-01-22 | Manchester Management Company, LLC | 578.36K | 6.20% |
| 2014-03-07 | James E. Besser | 529K | 5.90% |
| 2013-08-16 | Dr. Robert J. Kammer | 1.02M | 11.22% |
| 2012-09-13 | Professional Compounding Centers of America, Inc. 74-2188864 | 4.16M | 12.30% |
| 2012-09-06 | Donald Miloni | 6.22M | 18.10% |
| 2012-08-10 | Dr. Robert J. Kammer | 4.77M | 15.90% |
| 2012-05-02 | Robert Kammer | 16.1M | 53.60% |
| 2012-05-02 | DermaStar International, LLC | 15.98M | 53.40% |
| 2012-05-02 | Mark L. Baum | 16.33M | 53.90% |
| 2012-05-02 | DermaStar International, LLC | 15.98M | 53.40% |
| 2012-05-02 | Mark L. Baum | 16.33M | 53.90% |
| 2012-05-02 | Robert Kammer | 16.1M | 53.60% |
| 2012-05-02 | Robert Kammer | 16.1M | 53.60% |
| 2012-05-02 | DermaStar International, LLC | 15.98M | 53.40% |
| 2012-05-02 | Mark L. Baum | 16.33M | 53.90% |
| 2012-04-30 | Mark L. Baum | 16.33M | 53.94% |
| 2012-04-30 | Robert Kammer | 16.12M | 53.65% |
| 2012-04-30 | DermaStar International, LLC | 15.98M | 53.39% |
| 2012-04-30 | DermaStar International, LLC | 15.98M | 53.39% |
| 2012-04-30 | Robert Kammer | 16.12M | 53.65% |
| 2012-04-30 | Mark L. Baum | 16.33M | 53.94% |
| 2012-04-30 | Alexej Ladonnikov | 1.98M | 8.94% |
| 2011-02-10 | Joseph Grasela | 1.18M | 7.40% |
| 2008-02-14 | Jeffrey J. Abrams | 1.56M | 11.40% |
| 2008-02-14 | Joseph Grasela | 1.17M | 8.50% |
| 2008-02-14 | The Abrams Family Trust | 1.56M | 11.40% |
HROW Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $49.00 | 36.76M | $1.8B | $72.93M | $251.98M | $1.98B |
| 2024-12-31 | $33.55 | 35.65M | $1.2B | $47.25M | $228.83M | $1.38B |
| 2023-12-31 | $11.20 | 32.62M | $365.31M | $74.08M | $190.5M | $481.72M |
| 2022-12-31 | $14.76 | 27.46M | $405.32M | $96.27M | $112.23M | $421.28M |
| 2021-12-31 | $8.64 | 26.76M | $231.18M | $42.17M | $77.96M | $266.97M |
| 2020-12-31 | $6.86 | 25.9M | $177.64M | $4.1M | $23.53M | $197.07M |
| 2019-12-31 | $7.78 | 25.32M | $197.01M | $4.75M | $20.99M | $213.25M |
| 2018-12-31 | $5.69 | 21.92M | $124.71M | $6.64M | $15.25M | $133.32M |
| 2017-12-31 | $1.70 | 19.98M | $33.96M | $4.02M | $15.33M | $45.26M |
| 2016-12-31 | $2.50 | 12.74M | $31.86M | $8.85M | $13.69M | $36.69M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $35.26 | 37.23M | $1.31B | $94.64M | $300.67M | $1.52B |
| 2025-12-31 | $49.00 | 36.76M | $1.8B | $72.93M | $251.98M | $1.98B |
| 2025-09-30 | $48.18 | 37.15M | $1.79B | $74.29M | $251.87M | $1.97B |
| 2025-06-30 | $30.54 | 36.79M | $1.12B | $52.96M | $231.25M | $1.3B |
| 2025-03-31 | $26.60 | 35.83M | $952.97M | $66.73M | $230.01M | $1.12B |
| 2024-12-31 | $33.55 | 35.81M | $1.2B | $47.25M | $228.83M | $1.38B |
| 2024-09-30 | $44.96 | 35.7M | $1.61B | $72.6M | $196.06M | $1.73B |
| 2024-06-30 | $21.05 | 35.62M | $749.78M | $70.97M | $192.33M | $871.14M |
| 2024-03-31 | $12.80 | 35.47M | $454.02M | $68.54M | $191.66M | $577.14M |
| 2023-12-31 | $11.20 | 35.35M | $395.96M | $74.08M | $190.5M | $512.38M |
| 2023-09-30 | $14.37 | 34.26M | $492.24M | $65.61M | $189.71M | $616.34M |
| 2023-06-30 | $19.04 | 30.46M | $579.94M | $22.75M | $177.42M | $734.6M |